Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ
Home Search Quick Search Advanced Fulltext Browse Collections Persons My eDoc Session History Login Name: Password: Documentation Help Support Wiki Direct access to document ID:	Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Yearbook_2014     Display Documents ID: 682219.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Yearbook_2014 Updated treatment algorithm of pulmonary arterial hypertension Authors: Galie, N.; Corris, P. A.; Frost, A.; Girgis, R. E.; Granton, J.; Jing, Z. C.; Klepetko, W.; McGoon, M. D.; McLaughlin, V. V.; Preston, I. R.; Rubin, L. J.; Sandoval, J.; Seeger, W.; Keogh, A. Date of Publication (YYYY-MM-DD): 2013-12-24 Journal Abbrev.: J Am Coll Cardiol Volume: 62 Issue / Number: 25 Suppl Start Page: D60 End Page: 72 Audience: Not Specified Abstract / Description: The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple and in some ways conflicting. The treatment algorithm usually includes different types of recommendations with varying degrees of scientific evidence. In addition, the algorithm is required to be comprehensive but not too complex, informative yet simple and straightforward. The type of information in the treatment algorithm are heterogeneous including clinical, hemodynamic, medical, interventional, pharmacological and regulatory recommendations. Stakeholders (or users) including physicians from various specialties and with variable expertise in PAH, nurses, patients and patients' associations, healthcare providers, regulatory agencies and industry are often interested in the PAH treatment algorithm for different reasons. These are the considerable challenges faced when proposing appropriate updates to the current evidence-based treatment algorithm.The current treatment algorithm may be divided into 3 main areas: 1) general measures, supportive therapy, referral strategy, acute vasoreactivity testing and chronic treatment with calcium channel blockers; 2) initial therapy with approved PAH drugs; and 3) clinical response to the initial therapy, combination therapy, balloon atrial septostomy, and lung transplantation. All three sections will be revisited highlighting information newly available in the past 5 years and proposing updates where appropriate. The European Society of Cardiology grades of recommendation and levels of evidence will be adopted to rank the proposed treatments. Free Keywords: *Algorithms; Animals; Antihypertensive Agents/therapeutic use; Calcium Channel Blockers/therapeutic use; Humans; Hypertension, Pulmonary/*diagnosis/epidemiology/*therapy; Lung Transplantation/trends; Phosphodiesterase Inhibitors/therapeutic use; Treatment Outcome External Publication Status: published Document Type: Article Communicated by: Svea Hümmer Affiliations: MPI für physiologische und klinische Forschung External Affiliations: Institute of Cellular Medicine Newcastle University and The Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom. Baylor College of Medicine, Houston, Texas. Michigan State University, College of Human Medicine, Grand Rapids, Michigan. Division of Respirology, University of Toronto, Toronto, Canada. Fu Wai Hospital & National Center for Cardiovascular Disease Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China. Department of Thoracic Surgery, Medical University Vienna/Vienna General Hospital, Vienna, Austria. Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. Cardiovascular Medicine, The University of Michigan, Ann Arbor, Michigan. Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts. Medical School, University of California, San Diego, La Jolla, California. Clinical Research, National Institute of Cardiology of Mexico, Mexico City, Mexico. Max Planck Institute for Heart and Lung Research, Universities of Giessen and Marburg Lung Center, Giessen/Bad Nauheim, Germany. Heart Transplant Unit, St Vincent's Hospital, Sydney, Australia. Identifiers: ISSN:1558-3597 (Electronic) 0735-1097 (Linking) %R 10.1016/j.jacc.2013.10.031 URL:http://www.ncbi.nlm.nih.gov/pubmed/24355643 The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.